NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Forecast, Price & News $21.47 +0.63 (+3.02%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$20.31▼$21.5250-Day Range$20.84▼$30.3252-Week Range$13.73▼$33.99Volume2.40 million shsAverage Volume1.59 million shsMarket Capitalization$3.52 billionP/E RatioN/ADividend YieldN/APrice Target$31.81 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.38 Rating ScoreUpside/Downside48.2% Upside$31.81 Price TargetShort InterestBearish6.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 7 Articles This WeekInsider TradingSelling Shares$3.76 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to $0.60 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector273rd out of 969 stocksPharmaceutical Preparations Industry108th out of 452 stocks 4.2 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.81, ACADIA Pharmaceuticals has a forecasted upside of 48.2% from its current price of $21.47.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.54% of the outstanding shares of ACADIA Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 5.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.3 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ACADIA Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,758,210.00 in company stock.Percentage Held by Insiders27.50% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.29% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($0.41) to $0.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -31.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 8.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ACADIA Pharmaceuticals (NASDAQ:ACAD) StockACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer's disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.Read More ACAD Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACAD Stock News HeadlinesOctober 1, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 2.5%September 30, 2023 | americanbankingnews.comACADIA Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:ACAD)October 2, 2023 | Stansberry Research (Ad)Is NVIDIA Leading a "Magnificent Seven Bubble"?The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. September 28, 2023 | seekingalpha.comAcadia Pharma falls after patent hearing in dispute with MSNSeptember 28, 2023 | americanbankingnews.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Pass Above 200-Day Moving Average of $24.15September 23, 2023 | seekingalpha.comDaybue Drives Acadia Pharmaceuticals To Positive Earnings (Rating Upgrade)September 19, 2023 | finance.yahoo.comAcadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate CommunicationsSeptember 13, 2023 | ca.finance.yahoo.comACAD - ACADIA Pharmaceuticals Inc.October 2, 2023 | Stansberry Research (Ad)Is NVIDIA Leading a "Magnificent Seven Bubble"?The world’s massive tech leaders may be in a bubble, led by NVIDIA’s enormous rise this year. What happens next could affect all stocks. September 1, 2023 | finance.yahoo.comAcadia (ACAD) Down 0.7% Since Last Earnings Report: Can It Rebound?August 25, 2023 | finance.yahoo.comDry Eye Syndrome Global Market Report 2023August 25, 2023 | theglobeandmail.comBetting Big On Biotech: Six Undervalued Biotech Stocks To Keep On Your RadarAugust 25, 2023 | thestreet.comAcadia Pharmaceuticals Stock Has Fallen Too Far RecentlyAugust 23, 2023 | markets.businessinsider.comH.C. Wainwright upgrades Fulcrum Therapeutics (FULC) to a BuyAugust 22, 2023 | fool.comCan This Red-Hot Biotech Stock Keep Beating the Broader Markets?August 16, 2023 | markets.businessinsider.comZynerba Pharmaceuticals (ZYNE) was downgraded to a Hold Rating at Canaccord GenuityAugust 11, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Theseus Pharmaceuticals (THRX)August 10, 2023 | finance.yahoo.comHere's Why Acadia (ACAD) Looks Ripe for Bottom FishingAugust 10, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)August 9, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Terns Pharmaceuticals (TERN)August 8, 2023 | markets.businessinsider.comSyros Pharmaceuticals (SYRS) Gets a Buy from JMP SecuritiesAugust 8, 2023 | msn.comJP Morgan Maintains Acadia Pharmaceuticals (ACAD) Neutral RecommendationAugust 8, 2023 | markets.businessinsider.comJP Morgan Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To KnowAugust 3, 2023 | msn.comOppenheimer Reiterates Acadia Pharmaceuticals (ACAD) Perform RecommendationAugust 3, 2023 | msn.comCanaccord Genuity Maintains Acadia Pharmaceuticals (ACAD) Buy RecommendationAugust 3, 2023 | finance.yahoo.comAcadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat EstimatesAugust 2, 2023 | seekingalpha.comACADIA Pharmaceuticals Inc. 2023 Q2 - Results - Earnings Call PresentationSee More Headlines Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Company Calendar Last Earnings8/02/2023Today10/02/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees540Year FoundedN/APrice Target and Rating Average Stock Price Forecast$31.81 High Stock Price Forecast$95.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+49.8%Consensus RatingHold Rating Score (0-4)2.38 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,980,000.00 Net Margins-20.11% Pretax Margin-19.22% Return on Equity-27.77% Return on Assets-17.81% Debt Debt-to-Equity RatioN/A Current Ratio2.62 Quick Ratio2.57 Sales & Book Value Annual Sales$517.23 million Price / Sales6.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book8.60Miscellaneous Outstanding Shares163,730,000Free Float118,704,000Market Cap$3.48 billion OptionableOptionable Beta0.65 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Stephen R. Davis J.D. (Age 62)Pres, CEO & Director Comp: $1.46MMr. Mark C. Schneyer (Age 49)Exec. VP & CFO Comp: $701.03kMr. Brendan P. Teehan (Age 54)Exec. VP, COO & Head of Commercial Comp: $724.31kMr. Austin D. Kim (Age 59)Exec. VP, Gen. Counsel & Sec. Comp: $722.15kMr. James K. Kihara (Age 42)VP, Chief Accounting Officer & Corp. Controller Mr. Bob MischlerSr. VP of Strategy & Technology OperationsMr. Mark C. JohnsonVP of Investor RelationsMs. Julie FisherSr. VP of Marketing & Commercial StrategyMs. Holly ValdiviezSr. VP & Head of SalesMr. Rob AcklesSr. VP & Chief People OfficerMore ExecutivesKey CompetitorsInsmedNASDAQ:INSMImmunoGenNASDAQ:IMGNAmicus TherapeuticsNASDAQ:FOLDEvotecNASDAQ:EVOPerrigoNYSE:PRGOView All CompetitorsInsiders & InstitutionsBarclays PLCBought 23,862 shares on 9/21/2023Ownership: 0.116%James KiharaSold 2,000 sharesTotal: $51,760.00 ($25.88/share)Virginia Retirement Systems ET ALBought 57,400 shares on 8/22/2023Ownership: 0.035%California State Teachers Retirement SystemSold 11,186 shares on 8/21/2023Ownership: 0.086%Osaic Holdings Inc.Bought 7,234 shares on 8/21/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions ACAD Stock - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price forecast for 2023? 13 Wall Street analysts have issued 1 year target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $95.00. On average, they expect the company's share price to reach $31.81 in the next year. This suggests a possible upside of 49.8% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2023? ACADIA Pharmaceuticals' stock was trading at $15.92 on January 1st, 2023. Since then, ACAD stock has increased by 33.4% and is now trading at $21.24. View the best growth stocks for 2023 here. Are investors shorting ACADIA Pharmaceuticals? ACADIA Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 10,700,000 shares, an increase of 5.1% from the August 31st total of 10,180,000 shares. Based on an average daily trading volume, of 1,620,000 shares, the days-to-cover ratio is presently 6.6 days. View ACADIA Pharmaceuticals' Short Interest. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.13. The biopharmaceutical company earned $165.20 million during the quarter, compared to analyst estimates of $163.86 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 27.77% and a negative net margin of 20.11%. The business's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same period last year, the company earned ($0.21) earnings per share. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Invesco Biotechnology & Genome ETF (PBE), First Trust NYSE Arca Biotechnology Index Fund (FBT), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $21.24. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.48 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis. How many employees does ACADIA Pharmaceuticals have? The company employs 540 workers across the globe. How can I contact ACADIA Pharmaceuticals? ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872. This page (NASDAQ:ACAD) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.